» Articles » PMID: 30488277

Current State of Alzheimer's Fluid Biomarkers

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and heterogeneous pathophysiology. The number of people living with AD is predicted to increase; however, there are no disease-modifying therapies currently available and none have been successful in late-stage clinical trials. Fluid biomarkers measured in cerebrospinal fluid (CSF) or blood hold promise for enabling more effective drug development and establishing a more personalized medicine approach for AD diagnosis and treatment. Biomarkers used in drug development programmes should be qualified for a specific context of use (COU). These COUs include, but are not limited to, subject/patient selection, assessment of disease state and/or prognosis, assessment of mechanism of action, dose optimization, drug response monitoring, efficacy maximization, and toxicity/adverse reactions identification and minimization. The core AD CSF biomarkers Aβ42, t-tau, and p-tau are recognized by research guidelines for their diagnostic utility and are being considered for qualification for subject selection in clinical trials. However, there is a need to better understand their potential for other COUs, as well as identify additional fluid biomarkers reflecting other aspects of AD pathophysiology. Several novel fluid biomarkers have been proposed, but their role in AD pathology and their use as AD biomarkers have yet to be validated. In this review, we summarize some of the pathological mechanisms implicated in the sporadic AD and highlight the data for several established and novel fluid biomarkers (including BACE1, TREM2, YKL-40, IP-10, neurogranin, SNAP-25, synaptotagmin, α-synuclein, TDP-43, ferritin, VILIP-1, and NF-L) associated with each mechanism. We discuss the potential COUs for each biomarker.

Citing Articles

Impact of hemolysis on the levels of proteins associated with aging and age-related neurodegenerative diseases in a multicentric clinical research.

Anwar M, Renu K, Singh A, Nayal A, Thyagarajan B, Hu P Pract Lab Med. 2025; 44:e00455.

PMID: 39906488 PMC: 11791351. DOI: 10.1016/j.plabm.2025.e00455.


Improvements in Exercise for Alzheimer's Disease: Highlighting FGF21-Induced Cerebrovascular Protection.

Wang J, Meng X, Yang J, Tang Y, Zeng F, Wang Y Neurochem Res. 2025; 50(2):95.

PMID: 39903342 DOI: 10.1007/s11064-025-04350-w.


"Advances in biomarker discovery and diagnostics for alzheimer's disease".

Bhatia V, Chandel A, Minhas Y, Kushawaha S Neurol Sci. 2025; .

PMID: 39893357 DOI: 10.1007/s10072-025-08023-y.


Serum β-secretase 1 (sBACE1) activity in subjective cognitive decline: an exploratory study.

Cervellati C, Trentini A, Rosta V, Passaro A, Brombo G, Renzini C Geroscience. 2025; .

PMID: 39828771 DOI: 10.1007/s11357-025-01523-x.


Alterations of amino acids in older adults with Alzheimer's Disease and Vascular Dementia.

Ma X, Wang X, Tang G, Wang Y, Liu X, Wang S Amino Acids. 2025; 57(1):10.

PMID: 39825947 PMC: 11742867. DOI: 10.1007/s00726-024-03442-1.


References
1.
Berge G, Sando S, Albrektsen G, Lauridsen C, Moller I, Grontvedt G . Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study. BMC Neurol. 2016; 16(1):180. PMC: 5031325. DOI: 10.1186/s12883-016-0706-0. View

2.
Lauridsen C, Sando S, Moller I, Berge G, Pomary P, Grontvedt G . Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer's Disease, But Has Similar Diagnostic Accuracy to Aβ42. Front Aging Neurosci. 2017; 9:210. PMC: 5487529. DOI: 10.3389/fnagi.2017.00210. View

3.
Di Marco L, Venneri A, Farkas E, Evans P, Marzo A, Frangi A . Vascular dysfunction in the pathogenesis of Alzheimer's disease--A review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis. 2015; 82:593-606. DOI: 10.1016/j.nbd.2015.08.014. View

4.
Angiolillo A, Sgadari C, Taub D, Liao F, Farber J, Maheshwari S . Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med. 1995; 182(1):155-62. PMC: 2192108. DOI: 10.1084/jem.182.1.155. View

5.
Anand S, Barnes J, Young S, Garcia D, Tolley H, Kauwe J . Discovery and Confirmation of Diagnostic Serum Lipid Biomarkers for Alzheimer's Disease Using Direct Infusion Mass Spectrometry. J Alzheimers Dis. 2017; 59(1):277-290. DOI: 10.3233/JAD-170035. View